New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections

NEW ORLEANS, June 03, 2017 (GLOBE NEWSWIRE) — New data presented today at ASM Microbe 2017 showed that Paratek Pharmaceuticals, Inc.’s (PRTK) Phase 3 antibiotic omadacycline is highly active against common bacterial pathogens in acute skin and skin structure infections (ABSSSI), respiratory tract infections (RTI), and the key bacterial pathogens responsible for urinary tract infections (UTI).  The study evaluated the in vitro antibacterial activity of omadacycline against Gram-positive and Gram-negative bacterial isolates collected from patients with multiple infection types in the United States, Europe, and Israel medical centers participating in the 2016 SENTRY Antimicrobial Surveillance Program. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.